• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Nonlinear renal clearance of ultrafilterable platinum in patients treated with cis-dichlorodiammineplatinum (II).

作者信息

Reece P A, Stafford I, Russell J, Gill P G

出版信息

Cancer Chemother Pharmacol. 1985;15(3):295-9. doi: 10.1007/BF00263904.

DOI:10.1007/BF00263904
PMID:4053272
Abstract

Nonlinear renal clearance of ultrafilterable platinum was observed in 5 of 7 patients given cis-dichlorodiammineplatinum (II) in doses of 50-140 mg/m2 by short-term infusion (2 h). Average renal clearance determined during and 24 h after infusion ranged from 100 to 543 ml/min and always exceeded creatinine clearance, suggesting that ultrafilterable platinum was renally secreted. Saturable tubular reabsorption was postulated on the basis that renal clearance was highest at peak plasma and urinary levels and fell as the levels declined. Although an overall relationship between dose and renal clearance was not apparent, one patient receiving the highest dose (140 mg/m2) had elevated average renal clearance (485 ml/min), probably associated with saturation of reabsorption, whereas a patient receiving 50 mg/m2 had the lowest average renal clearance (100 ml/min), indicating that either active secretion was lower, or tubular reabsorption was saturated. One patient also showed urine-flow-dependent changes in renal clearance. Four patients had transient rises in ultrafilterable platinum levels, which were attributed to changes in renal tubular reabsorption. The results suggest that renal clearance of ultrafilterable platinum is probably dependent on cis-DDP dose, urine flow rate, and individual variability in the extent of active secretion and tubular reabsorption. A sensitive HPLC method was applied and ultrafilterable platinum was detected in the plasma of all patients 24 h after infusion. Renal tubular reabsorption may result in prolonged plasma levels of ultrafilterable platinum, which could contribute to the drug's antitumour effect.

摘要

相似文献

1
Nonlinear renal clearance of ultrafilterable platinum in patients treated with cis-dichlorodiammineplatinum (II).
Cancer Chemother Pharmacol. 1985;15(3):295-9. doi: 10.1007/BF00263904.
2
Creatinine clearance as a predictor of ultrafilterable platinum disposition in cancer patients treated with cisplatin: relationship between peak ultrafilterable platinum plasma levels and nephrotoxicity.
J Clin Oncol. 1987 Feb;5(2):304-9. doi: 10.1200/JCO.1987.5.2.304.
3
Reduced ability to clear ultrafilterable platinum with repeated courses of cisplatin.
J Clin Oncol. 1986 Sep;4(9):1392-8. doi: 10.1200/JCO.1986.4.9.1392.
4
Evaluation of the effect of furosemide on ultrafilterable platinum kinetics in patients treated with cis-diamminedichloroplatinum.
Cancer Chemother Pharmacol. 1989;23(1):37-40. doi: 10.1007/BF00258455.
5
Pharmacokinetics and pharmacodynamics of lobaplatin (D-19466) in patients with advanced solid tumors, including patients with impaired renal of liver function.洛铂(D-19466)在晚期实体瘤患者中的药代动力学和药效学,包括肝肾功能受损患者。
Clin Cancer Res. 1999 Sep;5(9):2349-58.
6
Disposition of unchanged cisplatin in patients with ovarian cancer.
Clin Pharmacol Ther. 1987 Sep;42(3):320-5. doi: 10.1038/clpt.1987.155.
7
Comparison of the pharmacokinetics of ultrafilterable cisplatin species detectable by derivatization with diethyldithiocarbamate or atomic absorption spectroscopy.通过二乙基二硫代氨基甲酸盐衍生化或原子吸收光谱法检测的可超滤顺铂物质的药代动力学比较。
Eur J Cancer. 1990 Jan;26(1):21-7. doi: 10.1016/0277-5379(90)90251-n.
8
Influence of hydration on ultrafilterable platinum kinetics and kidney function in patients treated with cis-diamminedichloroplatinum(II).
Cancer Chemother Pharmacol. 1990;26(4):278-82. doi: 10.1007/BF02897230.
9
Nonlinear kinetics of the thiamine cation in humans: saturation of nonrenal clearance and tubular reabsorption.硫胺阳离子在人体中的非线性动力学:非肾清除率和肾小管重吸收的饱和现象。
J Pharmacokinet Biopharm. 1990 Dec;18(6):501-23. doi: 10.1007/BF01073936.
10
Kinetics of cis-dichlorodiammineplatinum.
Clin Pharmacol Ther. 1979 Mar;25(3):351-7. doi: 10.1002/cpt1979253351.

引用本文的文献

1
Case Report and Supporting Documentation: Acute Kidney Injury Manifested as Oliguria Is Reduced by Intravenous Magnesium Before Cisplatin.病例报告及辅助文件:顺铂治疗前静脉注射镁可减轻以少尿为表现的急性肾损伤
Front Oncol. 2021 Feb 26;11:607574. doi: 10.3389/fonc.2021.607574. eCollection 2021.
2
Predicting tubular reabsorption with a human kidney proximal tubule tissue-on-a-chip and physiologically-based modeling.利用人源肾脏近端肾小管类器官芯片和基于生理学的模型预测管状重吸收。
Toxicol In Vitro. 2020 Mar;63:104752. doi: 10.1016/j.tiv.2019.104752. Epub 2019 Dec 17.
3
Xenobiotic transporters and kidney injury.

本文引用的文献

1
Renal handling of cis-diamminedichloroplatinum(II).顺二氯二氨合铂(II)的肾脏处理
Cancer Treat Rep. 1980;64(12):1223-6.
2
Pharmacokinetic evidence for an enterohepatic circulation in a patient treated with cis-dichlorodiammineplatinum (II).顺二氯二氨铂(II)治疗患者肝肠循环的药代动力学证据。
Res Commun Chem Pathol Pharmacol. 1980 May;28(2):319-28.
3
The mechanism of renal clearance of cisplatin (cis-dichlorodiammine platinum ii) and its modification by furosemide and probenecid.
外源性物质转运体与肾损伤。
Adv Drug Deliv Rev. 2017 Jul 1;116:73-91. doi: 10.1016/j.addr.2017.01.005. Epub 2017 Jan 20.
4
Membrane transporters as mediators of Cisplatin effects and side effects.膜转运蛋白作为顺铂作用和副作用的介质
Scientifica (Cairo). 2012;2012:473829. doi: 10.6064/2012/473829. Epub 2012 Nov 25.
5
Cisplatin nephrotoxicity is critically mediated via the human organic cation transporter 2.顺铂肾毒性主要通过人类有机阳离子转运体2介导。
Am J Pathol. 2005 Dec;167(6):1477-84. doi: 10.1016/S0002-9440(10)61234-5.
6
Long-term pharmacokinetic behavior of platinum after cisplatin administration.顺铂给药后铂的长期药代动力学行为。
Cancer Chemother Pharmacol. 1995;37(1-2):97-102. doi: 10.1007/BF00685635.
7
A phase I trial of 5-day continuous infusion cisplatin and interferon alpha.
Cancer Chemother Pharmacol. 1995;37(1-2):39-46. doi: 10.1007/BF00685627.
8
A model for ultrafilterable plasma platinum disposition in patients treated with cisplatin.
Cancer Chemother Pharmacol. 1987;20(1):26-32. doi: 10.1007/BF00252955.
9
Pharmacokinetics of anticancer drugs in children.儿童抗癌药物的药代动力学
Clin Pharmacokinet. 1987 Mar;12(3):168-213. doi: 10.2165/00003088-198712030-00002.
10
Effect of methotrexate on the pharmacokinetics and renal excretion of cisplatin.甲氨蝶呤对顺铂药代动力学及肾脏排泄的影响。
Eur J Clin Pharmacol. 1988;34(2):139-44. doi: 10.1007/BF00614550.
Biochem Pharmacol. 1982 Jul 1;31(13):2243-6. doi: 10.1016/0006-2952(82)90108-3.
4
Nonlinear renal elimination kinetics of methotrexate due to saturation of renal tubular reabsorption.
Eur J Clin Pharmacol. 1984;26(1):121-4. doi: 10.1007/BF00546719.
5
Mechanisms of renal excretion of cisdichlorodiamine platinum.顺二氯二氨铂的肾脏排泄机制。
Res Commun Chem Pathol Pharmacol. 1983 Aug;41(2):255-64.
6
Evaluation of reductive amperometric detection in the liquid chromatographic determination of antineoplastic platinum complexes.液相色谱法测定抗肿瘤铂配合物中还原电流检测法的评估
J Chromatogr. 1983 Apr 8;273(2):301-18. doi: 10.1016/s0378-4347(00)80951-2.
7
Mutagenic activity and identification of excreted platinum in human and rat urine and rat plasma after administration of cisplatin.顺铂给药后人体和大鼠尿液及大鼠血浆中铂的诱变活性及排泄铂的鉴定
Cancer Lett. 1983 Apr;18(3):329-38. doi: 10.1016/0304-3835(83)90244-6.
8
Sensitive high-performance liquid chromatographic assay for platinum in plasma ultrafiltrate.血浆超滤液中铂的灵敏高效液相色谱测定法。
J Chromatogr. 1984 Mar 9;306:417-23. doi: 10.1016/s0378-4347(00)80909-3.
9
Pharmacokinetics of Ip cisplatin in refractory ovarian carcinoma.腹腔内顺铂在难治性卵巢癌中的药代动力学
Cancer Treat Rep. 1983 Dec;67(12):1085-92.
10
Kinetics of cis-dichlorodiammineplatinum.
Clin Pharmacol Ther. 1979 Mar;25(3):351-7. doi: 10.1002/cpt1979253351.